Ciprofloxacin Alvogen (Ciprofloxacin Portfarma) Filmuhúðuð tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ciprofloxacin alvogen (ciprofloxacin portfarma) filmuhúðuð tafla 500 mg

alvogen ehf. - ciprofloxacinum hýdróklóríð - filmuhúðuð tafla - 500 mg

Ciprofloxacin Alvogen (Ciprofloxacin Portfarma) Filmuhúðuð tafla 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ciprofloxacin alvogen (ciprofloxacin portfarma) filmuhúðuð tafla 250 mg

alvogen ehf. - ciprofloxacinum hýdróklóríð - filmuhúðuð tafla - 250 mg

Ciprofloxacin Navamedic (Ciprofloxacin Villerton) Innrennslislyf, lausn 2 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ciprofloxacin navamedic (ciprofloxacin villerton) innrennslislyf, lausn 2 mg/ml

navamedic asa - ciprofloxacinum laktat - innrennslislyf, lausn - 2 mg/ml

Síprox Tafla 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 250 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 250 mg

Síprox Tafla 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

síprox tafla 500 mg

teva b.v.* - ciprofloxacinum hýdróklóríð - tafla - 500 mg

Ciflox (Ciproxin-Hydrocortison) Eyrnadropar, dreifa 2 mg + 10 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

ciflox (ciproxin-hydrocortison) eyrnadropar, dreifa 2 mg + 10 mg/ml

novartis healthcare a/s - ciprofloxacinum hýdróklóríð; hydrocortisonum inn - eyrnadropar, dreifa - 2 mg + 10 mg/ml

Jakavi Evrópusambandið - íslenska - EMA (European Medicines Agency)

jakavi

novartis europharm limited - ruxolitinib (sem fosfat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - Æxlishemjandi lyf - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (Úsbekistan)ráðlagt er ætlað fyrir meðferð fullorðinn sjúklinga með polycythaemia vera sem eru ónæmir fyrir eða þola hýdroxýúrea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Renagel Evrópusambandið - íslenska - EMA (European Medicines Agency)

renagel

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - Öll önnur lækningavörur - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis. renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

Pirfenidone axunio (previously Pirfenidone AET) Evrópusambandið - íslenska - EMA (European Medicines Agency)

pirfenidone axunio (previously pirfenidone aet)

axunio pharma gmbh - pirfenidone - idiopathic lungvefi - Ónæmisbælandi lyf - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Pirfenidone Viatris Evrópusambandið - íslenska - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - Ónæmisbælandi lyf - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).